Lv4
520 积分 2023-07-20 加入
Ramucirumab plus paclitaxel as switch maintenance versus continuation of first-line oxaliplatin-based chemotherapy in patients with advanced HER2-negative gastric or gastro-oesophageal junction cancer (ARMANI): a randomised, open-label, multicentre, phase 3 trial
36分钟前
待确认
TFOX versus FOLFOX in first-line treatment of patients with advanced HER2-negative gastric or gastro-oesophageal junction adenocarcinoma (PRODIGE 51- FFCD-GASTFOX): an open-label, multicentre, randomised, phase 3 trial
1小时前
待确认
What brown cannot do for you
15天前
已完结
HER2 testing: evolution and update for a companion diagnostic assay
15天前
已完结
Targeted Therapy for Advanced Solid Tumors on the Basis of Molecular Profiles: Results From MyPathway, an Open-Label, Phase IIa Multiple Basket Study
18天前
已完结
Trastuzumab deruxtecan (DS-8201a) in patients with advanced HER2-positive gastric cancer: a dose-expansion, phase 1 study
18天前
已完结
Hy's law: predicting serious hepatotoxicity
1个月前
已完结
Hy's law
1个月前
已完结
Sintilimab Plus Chemotherapy for Unresectable Gastric or Gastroesophageal Junction Cancer
1个月前
已完结
Sudden hearing loss due to oxaliplatin use in a patient with colon cancer
1个月前
已完结
皖公网安备34019202002308
